GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immune Design Corp (NAS:IMDZ) » Definitions » Days Payable

Immune Design (Immune Design) Days Payable : 156.09 (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Immune Design Days Payable?

Immune Design's average Accounts Payable for the three months ended in Dec. 2018 was $2.15 Mil. Immune Design's Cost of Goods Sold for the three months ended in Dec. 2018 was $1.26 Mil. Hence, Immune Design's Days Payable for the three months ended in Dec. 2018 was 156.09.

The historical rank and industry rank for Immune Design's Days Payable or its related term are showing as below:

IMDZ's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Immune Design's Days Payable declined from Dec. 2017 (17,147.98) to Dec. 2018 (156.09). It may suggest that Immune Design accelerated paying its suppliers.


Immune Design Days Payable Historical Data

The historical data trend for Immune Design's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immune Design Days Payable Chart

Immune Design Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Days Payable
Get a 7-Day Free Trial 2,222.32 2,352.46 2,896.10 14,975.86 484.80

Immune Design Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17,147.98 32,354.64 1,885.62 8,519.04 156.09

Competitive Comparison of Immune Design's Days Payable

For the Biotechnology subindustry, Immune Design's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immune Design's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immune Design's Days Payable distribution charts can be found below:

* The bar in red indicates where Immune Design's Days Payable falls into.



Immune Design Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Immune Design's Days Payable for the fiscal year that ended in Dec. 2018 is calculated as

Days Payable (A: Dec. 2018 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2017 ) + Accounts Payable (A: Dec. 2018 )) / count ) / Cost of Goods Sold (A: Dec. 2018 )*Days in Period
=( (2.334 + 1.478) / 2 ) / 1.435*365
=1.906 / 1.435*365
=484.80

Immune Design's Days Payable for the quarter that ended in Dec. 2018 is calculated as:

Days Payable (Q: Dec. 2018 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Sep. 2018 ) + Accounts Payable (Q: Dec. 2018 )) / count ) / Cost of Goods Sold (Q: Dec. 2018 )*Days in Period
=( (2.819 + 1.478) / 2 ) / 1.256*365 / 4
=2.1485 / 1.256*365 / 4
=156.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immune Design Days Payable Related Terms

Thank you for viewing the detailed overview of Immune Design's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Immune Design (Immune Design) Business Description

Traded in Other Exchanges
N/A
Address
1616 Eastlake Avenue East, Suite 310, Seattle, WA, USA, 98102
Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.
Executives
William R Ringo director
David Baltimore director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Edward Penhoet director ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Susan L. Kelley director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Carlos V Paya director, officer: President and CEO C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
David V Goeddel 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson 10 percent owner, other: Managing Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tim Kutzkey 10 percent owner, other: Managing Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Capital, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc 10 percent owner, other: General Partner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005

Immune Design (Immune Design) Headlines

From GuruFocus

RS Investment Exits LogMeIn, HMS Holdings in 3rd Quarter

By Tiziano Frateschi Tiziano Frateschi 10-04-2016